DGX vs NEOG vs EXAS vs QDEL vs BIO

For growth investors, Exact Sciences Corporation (EXAS) is the stronger pick with 17.

7% revenue growth year-over-year, versus -3. 2% for Neogen Corporation (NEOG). Bio-Rad Laboratories, Inc. (BIO) offers the better valuation at 9. 1x trailing P/E (27. 4x forward), making it the more compelling value choice. Analysts rate Exact Sciences Corporation (EXAS) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bio-Rad Laboratories, Inc.

(BIO) is the cheapest at 9. 1x versus Quest Diagnostics Incorporated at 21. 4x. On forward P/E, QuidelOrtho Corporation is actually cheaper at 6. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Quest Diagnostics Incorporated (DGX) delivered a total return of +42.

6%, compared to -90. 7% for QuidelOrtho Corporation (QDEL). Over 10 years, the gap is even starker: EXAS returned +1669% versus NEOG's -50. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Quest Diagnostics Incorporated (DGX) is the lower-risk stock at 0.

05β versus QuidelOrtho Corporation's 2. 28β — meaning QDEL is approximately 4712% more volatile than DGX relative to the S&P 500. On balance sheet safety, Bio-Rad Laboratories, Inc. (BIO) carries a lower debt/equity ratio of 21% versus 146% for QuidelOrtho Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Exact Sciences Corporation (EXAS) is pulling ahead at 17.

7% versus -3. 2% for Neogen Corporation (NEOG). On earnings-per-share growth, the picture is similar: Bio-Rad Laboratories, Inc. grew EPS 142. 6% year-over-year, compared to -114. 6% for Neogen Corporation. Over a 3-year CAGR, NEOG leads at 19. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bio-Rad Laboratories, Inc.

(BIO) is the more profitable company, earning 29. 4% net margin versus -122. 1% for Neogen Corporation — meaning it keeps 29. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DGX leads at 14. 5% versus -33. 7% for QDEL. At the gross margin level — before operating expenses — EXAS leads at 69. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, QuidelOrtho Corporation (QDEL) trades at 6.

0x forward P/E versus 582. 8x for Exact Sciences Corporation — 576. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BIO: 22. 9% to $312. 50.

In this comparison, DGX (1.

7% yield) pays a dividend. NEOG, EXAS, QDEL, BIO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), +1669% 10Y return). QuidelOrtho Corporation (QDEL) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXAS: +1669%, QDEL: -34. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DGX is a mid-cap quality compounder stock; NEOG is a small-cap quality compounder stock; EXAS is a mid-cap high-growth stock; QDEL is a small-cap quality compounder stock; BIO is a small-cap deep-value stock. DGX pays a dividend while NEOG, EXAS, QDEL, BIO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.